Table 3. Univariate and multivariate analysis of factors associated with OS and DFS in patients with srHCC.
| Variable | Disease-free survival | Overall survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| Gender (F or M)) | 0.674 (0.294–1.540) | 0.349 | – | – | 0.309 (0.106–0.892) | 0.029 | 1.845 (0.381–8.951) | 0.447 | |||
| Age (≤47.0 vs. >47.0) | 0.442 (0.184–1.066) | 0.069 | 0.176 (0.022–1.400) | 0.101 | 0.017 (0.026–1.301) | 0.088 | 0.134 (0.015–1.193) | 0.072 | |||
| BMI, kg/m2 | 0.927 (0.386–2.226) | 0.866 | – | – | 0.219 (0.029–1.677) | 0.143 | 0.140 (0.016–1.197) | 0.073 | |||
| Hepatitis (N vs. Y) | 6.842 (0.938–49.93) | 0.058 | 0.153 (0.151–15.44) | 0.720 | 2.458 (0.325–18.61) | 0.384 | – | – | |||
| CAHB (N vs. Y) | 1.068 (1.445–5.857) | 0.003 | 1.256 (0.394–4.019) | 0.699 | 2.009 (0.771–5.235) | 0.153 | 2.226 (0.655–7.567) | 0.200 | |||
| Cirrhosis (N or Y) | 1.169 (0.615–2.223) | 0.633 | – | – | 1.082 (0.427–2.741) | 0.868 | – | – | |||
| ALT, IU/mL (≤40 vs. >40) | 1.964 (1.031–3.740) | 0.040 | 2.321 (0.573–9.394) | 0.238 | 2.312 (0.885–6.034) | 0.087 | 1.388 (0.404–4.767) | 0.602 | |||
| AST, IU/mL (≤35 vs. >35) | 1.894 (0.963–3.725) | 0.064 | 0.992 (0.255–3.850) | 0.990 | 1.667 (0.614–4.552) | 0.317 | – | – | |||
| PLT, 109/L | 0.925 (0.405–2.112) | 0.853 | – | – | 1.453 (0.465–4.543) | 0.520 | – | – | |||
| Albumin, g/L | 0.646 (0.319–1.309) | 0.225 | – | – | 0.663 (0.234–1.878) | 0.439 | – | – | |||
| Creatinine, μmol/L | 0.749 (0.389–1.440) | 0.387 | – | – | 0.447 (0.158–1.266) | 0.130 | 0.748 (0.191–2.936) | 0.677 | |||
| TBIL, μmol/L (≤21 vs. >21) | 1.075 (0.846–1.336) | 0.553 | – | – | 0.925 (0.534–1.604) | 0.782 | – | – | |||
| PT, sec (≤14.6 vs. >14.6) | 1.170 (0.579–2.365) | 0.662 | – | – | 1.114 (0.394–3.145) | 0.838 | – | – | |||
| HGB, g/L (≤115 vs. >115) | 1.338 (0.699–2.563) | 0.379 | – | – | 0.663 (0.234–1.878) | 0.439 | – | – | |||
| AFP, IU/mL (≤400 vs. >400) | 3.034 (1.558–5.909) | 0.001 | 2.603 (0.832–8.134) | 0.100 | 3.148 (1.153–8.598) | 0.025 | 3.642 (0.959–13.82) | 0.058 | |||
| Satellite lesions (N or Y) | 2.805 (1.057–7.448) | 0.038 | 1.380 (0.149–12.73) | 0.776 | 2.722 (0.572–12.96) | 0.208 | – | – | |||
| Num of tumor (S or M) | 0.484 (0.199–1.171) | 0.107 | 0.646 (0.141–2.964) | 0.574 | 0.456 (0.128–1.628) | 0.226 | – | – | |||
| Operation way (LLR vs. OR) | 0.816 (0.417–1.600) | 0.555 | – | – | 0.756 (0.289–1.981) | 0.570 | – | – | |||
| Tumor size (<10 vs. ≥10 cm) | 2.969 (1.424–6.190) | 0.003 | 1.530 (0.376–6.221) | 0.552 | 3.343 (1.200–9.310) | 0.021 | 1.574 (0.381–6.505) | 0.531 | |||
| PVTT (N or Y) | 1.097 (0.387–3.114) | 0.861 | – | – | 1.126 (0.256–4.961) | 0.875 | – | – | |||
| MVI (N or Y) | 1.237 (0.684–2.361) | 0.518 | – | – | 1.187 (0.461–3.055) | 0.772 | – | – | |||
| HIPEC (Y or N) | 0.773 (0.399–1.498) | 0.446 | – | – | 0.469 (0.156–1.410) | 0.178 | 0.409 (0.116–1.445) | 0.165 | |||
Variables were adopted for their multivariable analysis by univariate analysis P<0.2. OS, overall survival; DFS, disease-free survival; srHCC, spontaneously ruptured hepatocellular carcinoma; F, female; M, male; S, solitary nodule; M, multiple nodules; BMI, body mass index; CAHB, chronic active hepatitis B; PT, prothrombin time; TBIL, total bilirubin; PLT, platelet; HGB, hemoglobin; AFP, alpha-fetoprotein; LLR, laparoscopic liver resection; OR, open resection; PVTT, portal vein tumor thrombus; MVI, microvascular invasion; HIPEC, hyperthermic intraperitoneal chemotherapy.